CTNI-19. PHASE I TRIAL OF DAY101 IN PEDIATRIC PATIENTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG)

BACKGROUND: We report phase I data examining pharmacokinetics, safety and preliminary efficacy of the dimeric, pan-RAF inhibitor DAY101 (formerly TAK-580/MLN2480) in pediatric patients with radiographically recurrent/progressive LGGs harboring MEK/ERK pathway alterations. METHODS: Oral DAY101 was ad...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Wright, Karen, Krzykwa, Emily, Greenspan, Lianne, Chi, Susan, Yeo, Kee Kiat, Prados, Michael, Mueller, Sabine, Haas-Kogan, Daphne
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650315/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.186
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars